F-1: Charming Medical Files for Nasdaq IPO, Reports Profit Growth Amidst Going Concern Warning

Sentiment:

Registration Statement 14 May 2025 6:19 PM

Charming Medical Limited, a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired wellness and beauty services, has filed for an initial public offering on Nasdaq, seeking to raise approximately $6.6 million, despite its auditor raising substantial doubt about its ability to continue as a going concern.

Capital raiseThe company is undertaking an initial public offering (IPO) of 1,600,000 Class A Ordinary Shares.The anticipated initial public offering price is between US$4.00 and US$6.00 per Class A Ordinary Share.The company estimates net proceeds from this offering to be approximately US$6.6 million, assuming the midpoint price of US$5.00 and excluding the underwriters' over-allotment option.The net proceeds are intended to be used as follows: approximately 40% for expanding business and geographic coverage (e.g., opening new wellness centers in Southeast Asia), 30% for potential strategic investment and acquisitions, 10% for research and development, and 20% for general working capital and corporate purposes.The company has granted the underwriters a 45-day option to purchase up to 240,000 additional Class A Ordinary Shares to cover over-allotments.

Worse than expectedThe company's auditor expressed substantial doubt about its ability to continue as a going concern, citing working capital deficits of US$2,281,970 as of September 30, 2024, and US$2,212,261 as of March 31, 2024.The company reported accumulated losses of US$610,827 as of September 30, 2024.

Summary

Charming Medical Limited is a British Virgin Islands holding company that operates TCM-inspired beauty, wellness, and postpartum services and products in Hong Kong through four wellness centers under the Beauty Lab brand.
The company offers a wide range of services including womb-warming therapy, pelvic detox, moxibustion, prenatal massage, and abdominal binding, alongside TCM-inspired supplements and beauty products.
Charming Medical also provides consultancy services for TCM-inspired therapy technical training and dietary therapy training to other beauty salons and massage centers.
For the fiscal year ended March 31, 2024, the company reported total revenue of $6,015,375 and achieved a net profit of $821,743, a significant improvement from a net loss of $335,605 in the prior fiscal year.
For the six months ended September 30, 2024, revenue increased by 12.0% to $2,958,508, with net income rising to $468,817 from $377,651 in the same period of 2023.
The company plans to offer 1,600,000 Class A Ordinary Shares in its initial public offering, with an anticipated price range of US$4.00 to US$6.00 per share, and intends to list on the Nasdaq Capital Market under the symbol MCTA.
Charming Medical operates with a dual-class share structure, where Class A Ordinary Shares carry one vote per share and Class B Ordinary Shares carry twenty votes per share.
Post-IPO, Ms. Kit Wong, the CEO, Director, and Chairman, will retain significant control, holding 91.65% of the total voting power.
The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to working capital deficits of US$2,281,970 as of September 30, 2024, and US$2,212,261 as of March 31, 2024.
Management states plans to meet cash requirements for the next 12 months through operations, financial support from the controlling shareholder, financial institutions, and investors, and by improving operational efficiency and cost reductions.

Sentiment

Score: 4

Explanation: While the company demonstrates revenue growth and a shift to profitability, the auditor's 'going concern' warning due to significant working capital deficits and accumulated losses, coupled with inherent regulatory uncertainties related to operating in Hong Kong under potential PRC influence and high dilution for new investors, indicates a cautious outlook despite stated growth prospects.

Positives

Total revenue increased by 70.4% from US$3,530,822 in FY2023 to US$6,015,375 in FY2024.
The company transitioned from a net loss of US$335,605 in FY2023 to a net profit of US$821,743 in FY2024.
Net income for the six months ended September 30, 2024, increased by 24.1% to US$468,817 compared to US$377,651 in the prior comparable period.
Average customer spending increased by 11.7% from US$1,340 for the six months ended September 30, 2023, to US$1,497 for the six months ended September 30, 2024.
The company successfully launched consultancy services in September 2023, generating US$112,569 in revenue for FY2024 from nil in FY2023.
The company highlights competitive strengths including a professional team with certified services, comprehensive one-stop health and wellness offerings, high-quality assurance for products and services, and integration of TCM principles with modern technology.
Government support in Hong Kong for TCM wellness, including integration into tourism and wellness centers, is noted as a growth driver.
The company benefits from a growing consumer preference for natural health and balance solutions, aligning with TCM's holistic approach.
A diversified supply chain management ensures stability and flexibility in product supply, with no single supplier accounting for more than 10% of total procurement.

Negatives

The company's auditor expressed substantial doubt about its ability to continue as a going concern due to working capital deficits of US$2,281,970 as of September 30, 2024, and US$2,212,261 as of March 31, 2024.
The company had accumulated losses of US$610,827 as of September 30, 2024.
As a holding company, Charming Medical relies on dividends from its Hong Kong subsidiaries, which could be restricted by future PRC government interventions on cash transfers out of Hong Kong.
The company operates in a dynamic industry with a limited operating history, meaning historical financial performance may not be indicative of future results.
The TCM-inspired wellness and beauty industry faces intense competition and pricing pressures.
Challenges exist in building customer trust and boosting acceptance due to limited evidence-based validation of TCM efficacy and the longer time required for visible results compared to modern cosmetic treatments.
The relative lack of stringent laws and regulations in Hong Kong's wellness and beauty services sector poses a risk of inconsistent service quality.
The company does not carry product liability insurance or business interruption insurance, exposing it to significant financial risks from claims or disruptions.
The CEO, Ms. Kit Wong, holds other management positions and directorships, which may lead to conflicts of interest and divert her time and attention from the company's operations.
New investors in the IPO will experience immediate and substantial dilution in net tangible book value, approximately 93.6% from the assumed offering price of US$5.00 per share.
The Class A Ordinary Shares may be thinly traded, making it difficult for investors to sell shares at or near ask prices or at all.
There is a risk of delisting from Nasdaq under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect the company's auditor for two consecutive years.
The dual-class share structure grants the controlling shareholder, Ms. Kit Wong, significant voting power (91.65% post-IPO), which may deprive other shareholders of an opportunity to receive a premium for their shares and reduce investment value.

Risks

Uncertainties and potential intervention by the PRC government in Hong Kong operations, which could result in a material change in operations and/or the value of Class A Ordinary Shares.
Risk of delisting from U.S. exchanges under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect the company's auditor for two consecutive years.
Substantial doubt about the company's ability to continue as a going concern due to working capital deficits as of September 30, 2024, and March 31, 2024.
Intense competition in the TCM-inspired wellness and beauty industry could adversely affect market share, revenues, and growth prospects.
Challenges in building customer trust and boosting customer acceptance due to limited evidence-based validation of TCM efficacy and longer timeframes for visible results.
The relative lack of stringent laws and regulations in Hong Kong's wellness and beauty services sector poses a risk of inconsistent service quality and potential adverse effects on reputation.
Exposure to inherent risks relating to product liability and personal injury claims, with no product liability or business interruption insurance.
Significant risks associated with contracting with third-party suppliers, including potential contaminations, defects, or non-compliance with safety standards.
Dependence on the continued and collaborative efforts of senior management and key employees, including skilled TCM practitioners and technicians; loss of their services could harm the business.
Potential conflicts of interest arising from CEO Kit Wong's concurrent management positions and directorships in other companies.
Business expansion into other countries requires substantial investment and resources, subject to risks and uncertainties related to local demand, regulatory compliance, and cultural differences.
An economic downturn may adversely affect consumer discretionary spending and demand for the company's products and services.
The company collects, stores, processes, and uses customer data, subjecting it to laws and regulations related to privacy, information security, and data protection; any failure to comply or data breach could harm the business.
The Hong Kong legal system embodies uncertainties, including the impact of the Hong Kong National Security Law, which could limit the availability of legal protections.
Changes in currency conversion rates between Hong Kong dollars and United States dollars may affect the value of investments.
The company may experience extreme stock price volatility unrelated to its actual or expected operating performance, making it difficult for investors to assess value.
Class A Ordinary Shares may be thinly traded, potentially making it difficult for investors to sell shares at or near ask prices or at all.
Inability to satisfy or continue to satisfy the initial listing requirements and other rules of the Nasdaq Capital Market could lead to delisting.
New investors will experience immediate and substantial dilution in the net tangible book value of Class A Ordinary Shares purchased.
The company's dividend policy indicates no expectation of cash dividends in the foreseeable future, requiring investors to rely on price appreciation for return.
As an emerging growth company and foreign private issuer, the company will be subject to lessened disclosure requirements and may follow home-country corporate governance practices, potentially making Class A Ordinary Shares less attractive to investors.
Management has broad discretion in the use of net proceeds from the offering and may not use them effectively.
There is no assurance that the company will not be deemed a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. holders.

Future Outlook

The company plans to expand its international market share by entering new geographic regions, particularly Southeast Asia, through thorough market research and adapted marketing strategies. It intends to build strategic partnerships with cosmetic brands, health institutions, retailers, and research institutions to foster resource sharing and enhance product competitiveness. Significant investment is planned for technological innovation and R&D, including ingredient research for skincare products and the adoption of advanced beauty instruments. The company aims to establish a strong brand image through differentiation, marketing campaigns, quality assurance, and enhanced customer experience, including hosting seminars and workshops. Additionally, it plans to diversify its product and service offerings, specifically targeting male consumers with new TCM-inspired wellness solutions for common health concerns.

Management Comments

Management believes that TCM-inspired herbal therapies can help balance the female endocrine system and improve women's constitution and overall health.
Management monitors the cash position of the Operating Subsidiaries regularly and prepares budgets on a monthly basis to ensure necessary funds for foreseeable obligations and adequate liquidity.
Management believes the company's ability to continue as a going concern is not contingent upon obtaining funding from sales of its stock securities in this Offering, citing improved profitability and ongoing efforts to enhance operational efficiency and reduce costs.

Industry Context

Charming Medical Limited operates within the Traditional Chinese Medicine (TCM) wellness and beauty industry in Hong Kong, a market experiencing rapid growth driven by increasing consumer demand for natural, holistic health solutions. The overall TCM service market in Hong Kong grew from 32.5 billion HKD in 2019 to 36.9 billion HKD in 2023, with a projected CAGR of 6.5% to reach 57.3 billion HKD by 2030. Specific segments like TCM Womens Health, Fertility-related TCM Services, and TCM Beauty are also expanding significantly, fueled by factors such as rising gynecological health issues, delayed childbearing trends, government support for TCM, and the influence of social media promoting natural beauty therapies. The market is highly competitive, with both public and private providers, but wellness centers like Charming Medical are gaining popularity for offering comprehensive, personalized services. Future trends indicate a shift towards one-stop health service solutions and increased customization in TCM wellness centers.

Comparison to Industry Standards

The company's TCM practitioners hold Registered Chinese Medicine Practitioner Certificates issued by the Hong Kong Chinese Medicine Council, adhering to statutory professional qualifications under the Chinese Medicine Ordinance.
Technicians performing Indonesian traditional abdominal binding therapy have completed specialized training in this technique.
TCM practitioners performing Japanese facial bone adjustment services hold memberships with the Hong Kong Chinese Orthopedics Society.
The company's product suppliers hold Good Manufacturing Practice (GMP) certificates and comply with ISO 9001 quality management standards, indicating adherence to globally recognized quality benchmarks.
The document notes that adherence to Hong Kong's 'Specification of Competency Standards for the Beauty Industry' is voluntary rather than mandatory, suggesting a less stringent regulatory environment compared to some other industries or regions, which could lead to inconsistent service quality across the broader industry.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Independent Director Nominee	NA	Josephine Yan Yeung	Upon Nasdaq Capital Market listing	Appointment as independent director and chair of the audit committee, and a member of the compensation and nominating committees.
Independent Director Nominee	NA	Leut Ming Gung	Upon Nasdaq Capital Market listing	Appointment as independent director and chair of the compensation committee, and a member of the audit and nominating committees.
Independent Director Nominee	NA	Shu Tai Victor Yu	Upon Nasdaq Capital Market listing	Appointment as independent director and chair of the nominating committee, and a member of the audit and compensation committees.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Committee Establishment	Plans to establish an audit committee, a compensation committee, and a nominating committee under the Board of Directors, with charters to be adopted.	Upon Nasdaq Capital Market listing	Enhances corporate governance structure in line with Nasdaq listing requirements, providing independent oversight of financial reporting, executive compensation, and director nominations.
Policy Adoption	Intends to adopt a written Code of Business Conduct and Ethics, an Insider Trading Policy, and an Executive Compensation Recovery Policy.	Prior to effectiveness of registration statement	Establishes clear ethical guidelines, prevents insider trading, and allows for recovery of executive compensation in certain circumstances, promoting accountability and compliance.
Share Structure Reclassification	Approved a redesignation and reclassification of shares and a 1-for-1,500 forward share split on October 18, 2024, resulting in 60,000,000 Class A Ordinary Shares (one vote per share) and 15,000,000 Class B Ordinary Shares (twenty votes per share).	2024-10-18	Creates a dual-class share structure that concentrates voting power with the controlling shareholder, potentially limiting the influence of public shareholders.
Controlled Company Status	Will be a controlled company under Nasdaq Listing Rules, with Ms. Kit Wong holding over 50% of the voting power for the election of directors, which permits reliance on exemptions from certain corporate governance requirements (e.g., majority independent board, independent nominating/compensation committees).	Upon completion of IPO	May afford less protection to shareholders compared to companies fully complying with Nasdaq corporate governance standards, although the company does not currently intend to rely on these exemptions.
Foreign Private Issuer Status	Will report as a foreign private issuer under SEC rules, exempting it from certain provisions applicable to U.S. domestic public companies (e.g., fewer Exchange Act reports, different disclosure levels, exemption from proxy solicitation rules, Section 16).	Upon consummation of IPO	Provides flexibility in reporting and governance but may offer less extensive and timely information or protections to U.S. investors.

Legal Proceedings

The company is currently not a party to any material legal or administrative proceedings.

Related Party Transactions

Amount due from Ms. Kit Wong (Controlling Shareholder, CEO, Director) was US$73,523 as of September 30, 2024, and US$885,056 as of March 31, 2024. These balances were unsecured, interest-free, with no specific repayment terms, and were related to payments made on behalf of the company and receipt of service fees. The balance as of September 30, 2024, has been fully settled or collected as of the prospectus date.
Staff costs and employee benefits paid to Ms. Wong Ting Ting (sister of Ms. Wong, employee) were US$23,091 for the six months ended September 30, 2024, and US$30,674 for the fiscal year ended March 31, 2024.
Staff costs and employee benefits paid to Ms. Liu Qiong (mother of Ms. Wong, employee) were US$14,310 for the six months ended September 30, 2024, and US$16,116 for the fiscal year ended March 31, 2024.
Remuneration to senior management (including Ms. Kit Wong) was US$117,518 for the six months ended September 30, 2024, and US$173,034 for the fiscal year ended March 31, 2024.
Non-cash dividends totaling US$694,922 were declared on March 31, 2024, by Pilate and Dream International to their sole shareholder, Ms. Wong, to offset receivable balances owed by her to the company.

Stakeholder Impact

Shareholders: New investors face significant dilution (93.6%). The dual-class share structure concentrates voting power with the controlling shareholder, potentially limiting the influence of public shareholders. There is a risk of delisting under the HFCAA, which could negatively impact share value and liquidity. No cash dividends are expected in the foreseeable future, meaning returns depend on price appreciation.
Employees: The company's success is dependent on attracting, motivating, and retaining skilled TCM practitioners, technicians, and support staff. Employment agreements for executives include non-compete and non-solicitation clauses. An Executive Compensation Recovery Policy has been adopted.
Customers: The company focuses on providing personalized, high-quality services and products. However, the relative lack of stringent regulations in Hong Kong's beauty services sector poses a risk of inconsistent service quality, which could affect customer trust and satisfaction.
Suppliers: The company sources products from third-party organizations and OEM factories, with a diversified supply chain to ensure stability and flexibility. Suppliers are required to hold GMP certificates and comply with ISO 9001 standards.
Creditors: The auditor's 'going concern' opinion due to working capital deficits raises concerns about the company's ability to meet its financial obligations, although management has plans for additional financing and support from the controlling shareholder.

Next Steps

Listing Class A Ordinary Shares on the Nasdaq Capital Market under the symbol MCTA.
Expanding business and geographic coverage, including opening new wellness centers in other geographic markets like Southeast Asia.
Pursuing potential strategic investments and acquisitions.
Investing in technological innovation and improving R&D capability, such as ingredient research for skincare product development and adopting advanced beauty instruments.
Establishing a strong brand image through differentiation, marketing campaigns, quality assurance, and enhanced customer experience.
Diversifying product and service offerings, particularly by developing and introducing additional TCM-inspired wellness solutions tailored to male consumers.
Obtaining additional financing and negotiating the terms of existing short-term liabilities to address current liquidity needs and the going concern issue.

Key Dates

Date	Description
2016-07-14	Pilate International Trading Limited incorporated in Hong Kong.
2017-03-14	Dream International Trading (Hong Kong) Limited incorporated in Hong Kong.
2018-08-14	Trademark 'Wong Kit' (Class 44) registered.
2019-09-19	My Beauty Technology Limited incorporated in Hong Kong.
2021-03-07	Choliya Limited incorporated in Hong Kong.
2021-06-10	PRC Data Security Law enacted.
2021-07-06	Opinions on Strictly Cracking Down on Illegal Securities Activities issued by PRC.
2021-08-20	PRC Personal Information Protection Law passed.
2021-09-01	PRC Data Security Law became effective.
2021-09-22	PCAOB adopted final rule implementing HFCAA.
2021-11-01	PRC Personal Information Protection Law became effective.
2021-12-02	SEC issued amendments to finalize HFCA Act rules.
2021-12-16	PCAOB Determination Report found inability to inspect registered public accounting firms headquartered in Mainland China and Hong Kong.
2021-12-24	Draft Overseas Listing Regulations issued by CSRC.
2021-12-28	Measures for Cybersecurity Review (2021) published by CAC.
2022-02-15	Measures for Cybersecurity Review (2021) took effect.
2022-08-26	PCAOB signed a Statement of Protocol with the China Securities Regulatory Commission and the Ministry of Finance of the PRC.
2022-12-15	PCAOB vacated its previous determination and concluded it was able to conduct inspections and investigations completely in the PRC in 2022.
2022-12-29	Accelerating Holding Foreign Companies Accountable Act signed into law, amending HFCAA to require delisting after two consecutive non-inspection years.
2023-02-17	CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies.
2023-03-31	Trial Administrative Measures came into effect.
2024-02-28	Charming Medical Limited incorporated in the British Virgin Islands.
2024-03-19	Legislative Council of Hong Kong passed the Safeguarding National Security bill.
2024-03-23	Safeguarding National Security Ordinance came into effect in Hong Kong.
2024-03-31	Non-cash dividends of US$694,922 declared to Ms. Wong by Pilate and Dream International to offset receivable balances.
2024-04-04	Lease for the store located in Central, Hong Kong expired and the store was closed as a cost-saving measure.
2024-04-30	Company purchased a three-month principal guaranteed bond from Bank of China (Hong Kong) Limited with a principal of approximately US$600,119.
2024-05-06	Beautylab Group Medical Limited incorporated in the BVI as an intermediate wholly-owned holding company by Charming Medical.
2024-06-15	Lease for Units Nos. 1313 & 1315, 13/F, Tower 1 Grand Central Plaza, Shatin, New Territories, Hong Kong began.
2024-06-18	Ms. Wong acquired 20% of Choliya's equity interests from an independent third party.
2024-06-18	Company purchased another three-month principal guaranteed bond from Bank of China (Hong Kong) Limited with a principal of approximately US$789,456.
2024-07-16	Lease for Unit No.1505, Carnarvon Plaza, Tsimshatsui, Kowloon, Hong Kong began.
2024-07-30	The first bond purchased on April 30, 2024, matured, and the company purchased another bond from Bank of Communications Co. Ltd.
2024-09-10	Dream International Trading, My Beauty Technology, and Pilate allotted 99% of their enlarged share capital to Beautylab BVI.
2024-09-16	Ms. Wong transferred her 2,000 ordinary shares in Choliya to Pilate, making Choliya a 100% wholly-owned subsidiary of Pilate.
2024-09-19	Beautylab BVI acquired 1% of the share capital of Dream International Trading, My Beauty Technology, and Pilate from Ms. Wong, completing the reorganization making Operating Subsidiaries indirectly wholly owned by Charming Medical.
2024-09-19	Ms. Kit Wong transferred 1,725 shares (19.40% of issued shares) to five independent individuals.
2024-10-18	Shareholders and director approved a redesignation and reclassification of shares and a 1-for-1,500 forward share split, changing authorized shares to 60,000,000 Class A and 15,000,000 Class B ordinary shares.
2024-11-01	Sole director approved the allotment and issuance of 2,000,000 Class B ordinary shares to Ms. Wong.
2024-11-01	Ms. Wong transferred 400,140 Class A Ordinary Shares to a pre-IPO investor for US$1,300,000.
2024-11-01	Lease for Suite 1803-06, 18/F., Hang Lung Centre, Causeway Bay, Hong Kong began.
2024-11-21	Date of auditor's report for consolidated financial statements as of and for the fiscal years ended March 31, 2024 and 2023.
2024-12-17	Lease for the whole of the 5th Floor, Hang Shun Commercial Building, Tsimshatsui, Kowloon, Hong Kong began.
2025-02-01	Effective date of employment agreements for Kit Wong (CEO) and Ching Man Cheung (CFO).
2025-03-30	Company completed the registration of payment methods (Alipay, Payme, WeChat Pay, FPS) under its own name.
2025-03-31	Effective Date for Executive Compensation Recovery Policy.
2025-04-28	Date of auditor's review report for unaudited interim condensed consolidated financial statements as of and for the six months ended September 30, 2024 and 2023.
2025-05-14	F-1 Registration Statement filed with the U.S. Securities and Exchange Commission.
2026-08-18	Domain name hkbeautylab.com expires.
2026-12-16	Lease for the 5th Floor, Hang Shun Commercial Building, Tsimshatsui, Kowloon, Hong Kong ends.
2027-06-14	Lease for Units Nos. 1313 & 1315, 13/F, Tower 1 Grand Central Plaza, Shatin, New Territories, Hong Kong ends.
2031-07-12	Exclusive Patent Licensing Agreement for 'Traditional Chinese Medicine Composition and Its Preparation Method for Treating Gynecological Diseases' expires.

Recommendation

hold

Keywords

Traditional Chinese Medicine, TCM, Wellness, Beauty, Postpartum Care, Hong Kong, IPO, Nasdaq, Healthcare, Supplements, Services, F-1 Filing, SEC, Beauty Lab Group, Dual-Class Shares, Going Concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.